Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $9.24 Analyst target: $21.71 Upside: 134.96%
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. The company is headquartered in South San Francisco, California.
See the full interactive analysis & chart →Informational only — not investment advice.